NanoTemper joins forces with PharmAI to boost drug research capabilities

Germany-based NanoTemper Technologies has reportedly announced an alliance with PharmAI- a Dresden-headquartered startup that lays its expertise in virtual screen software. Through this partnership, the companies will work towards countering some of the biggest challenges faced to accelerate drug development.

Notably, researchers are traditionally required have to comb through large amounts of data to attain the right drug candidates. This process makes it difficult for small laboratories to facilitate drug research and also discourage large pharmaceutical firms from working on rare healthcare conditions.  

According to Dr. Joachim Haupt, CEO, PharmAI, with researchers unwilling to spend time on measurements, the company’s novel software will help make predictions related to drug candidates and reduce various possibilities to a manageable size.

Joachim further added that instruments and software by NanoTemper are capable of validating the predictions so that researchers can rely on them and move ahead with their results.

Citing reports, both NanoTemper and PharmAI will soon integrate their technologies to establish a new generation of tools. The biophysical instruments by NanoTemper offers several optical measuring methods to molecules, permitting researchers to achieve vital information regarding the target’s stability, size, and bioactive potential.

In addition to the above, through the use of AI from DiscoveryEngine software by PharmAI, the identification of relevant drug candidates in large databases will be simplified.

Incorporated in the year 2008, NanoTemper Technologies aims at allowing people to carry out meaningful research. The German company develops tools that meet the challenging characterizations which are used in scientific research and drug discovery.  

On the other hand, PharmAI’s goal is to offer early-stage drug discovery more efficiently by growing success rates along with making it cost-effective. The firm designs and develops AI-led software to carry out analysis of 3D protein structures.

Source Credit: